Jeffrey R. Infante, MD

home / authors / jeffrey-r-infante-md

Articles

Dr. Infante on AM0010 in Patients With RCC

Dr. Infante on AM0010 in Patients With RCC

Jeffrey R. Infante, MD
May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Read More

Dr. Infante on Avelumab's Potential in Ovarian Cancer

Dr. Infante on Avelumab's Potential in Ovarian Cancer

Jeffrey R. Infante, MD
July 22nd 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Read More

Dr. Infante on the Next Step in Melanoma Research

Dr. Infante on the Next Step in Melanoma Research

Jeffrey R. Infante, MD
June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Read More

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

Jeffrey R. Infante, MD
June 8th 2011

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Read More

Dr. Infante Talks About BRAF Mutation Testing

Dr. Infante Talks About BRAF Mutation Testing

Jeffrey R. Infante, MD
June 7th 2011

Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC